Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

Fiche publication

Date publication

septembre 2014


Membres identifiés du Cancéropôle Est :
Pr BRUNOTTE François, Dr CASASNOVAS Olivier, Pr COCHET Alexandre, Dr ROSSI Cédric

Tous les auteurs :
Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, Toubeau M, Ferrant E, Brunotte F, Casasnovas RO


PURPOSE: The presence of a bulky tumour at staging in Hodgkin lymphoma (HL) is a predictor of a poor outcome. The total metabolic tumour volume at baseline (TMTV0) computed on PET may improve the evaluation of tumour burden. To explore the clinical usefulness of TMTV0, we compared the prognostic value of TMTV0, tumour bulk and interim PET response in a retrospective single-centre study. METHODS: From 2007 to 2010, 59 consecutive patients with a first diagnosis of HL were treated in our institution. PET was done at baseline (PET0) and after two cycles of chemotherapy (PET2), and treatment was not modified according to the PET2 result. TMTV0 was measured with a semiautomatic method using a 41 % SUVmax threshold. SUVmax reduction between PET0 and PET2 (DeltaSUVmaxPET0-2) was also computed. Based on ROC analysis, patients with a DeltaSUVmaxPET0-2 >71 % were considered good responders and a TMTV0 >225 ml was considered to represent hypermetabolic bulky disease. RESULTS: Median TMTV0 was 117 ml and 17 patients (29 %) had a TMTV0 >225 ml. TMTV0 (>225 ml vs. 71 % and TMTV0


Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43